The IMCL level may be a marker for impaired muscle contractile force caused by aging and HFD.Baroreflex response consists of cardiac chronotropic (effect on heart rate), cardiac inotropic (on contractility), venous (on venous return) and vascular (on vascular resistance) arms. Because of its measurement simplicity, cardiac chronotropic arm is most often analysed. The aim was to introduce a method to assess vascular baroreflex arm, and to characterize its changes during stress. We evaluated the effect of orthostasis and mental arithmetics (MA) in 39 (22 female, median age 18.7 yrs.) and 36 (21 female, 19.2 yrs.) healthy volunteers, respectively. We recorded systolic and mean blood pressure (SBP and MBP) by volume-clamp method and R-R interval (RR) by ECG. Cardiac output (CO) was recorded using impedance cardiography. From MBP and CO, peripheral vascular resistance (PVR) was calculated. The directional spectral coupling and gain of cardiac chronotropic (SBP to RR) and vascular arms (SBP to PVR) were quantified. The strength of the causal coupling from SBP to PVR was significantly higher than SBP to RR coupling during whole protocol (P less then 0.001). Along both arms, the coupling was higher during orthostasis compared to supine (P less then 0.001 and P = 0.006), no MA effect was observed. No significant changes in the spectral gain (ratio of RR or PVR change to a unit SBP change) across all phases were found (0.111 ? P ? 0.907). https://www.selleckchem.com/products/nps-2143.html We conclude that changes in PVR are tightly coupled with SBP oscillations via the baroreflex providing an approach for the baroreflex vascular arm analysis with a potential to reveal new aspects of blood pressure dysregulation.Objectives An increasing number of children are living with complex chronic diseases (CCDs) due to medical advances. Despite a need for code status discussions (CSDs), there is great variability in the frequency and documentation of such conversations. The objective was to identify gaps in the documentation of CSDs within the electronic health record (EHR), focusing on patients with CCDs. Methods This was a retrospective review of all patients admitted from the emergency department of a tertiary care children's hospital in 2016. An EHR query using the Apache Hadoop cluster and manual review identified documentation of CSDs, including (1) code status orders, (2) advance directives, and (3) CSDs in provider notes. Patient complexity was stratified using the Pediatric Medical Complexity Algorithm 3.0. Comparative analysis was performed using chi-square, Kruskal-Wallis tests and multivariable logistic regression. Results There were 12,648 unique patients of whom 4157 (32.9%) had CCD. Only 209 (1.7%) patients had a code status documented, of whom 200 (95.7%) had CCD. Of 528 (4.2%) patients ?18 years of age, 428 (81.1%) had CCD and only 65 (12.3%) had CSDs. Palliative care consultation increased odds of CSDs (OR 21.4, 95% CI 13.8-33.2, p? less then ?0.0001), whereas African American race decreased odds of CSDs (OR 0.42, 95% CI 0.27-0.64, p? less then ?0.0001). Conclusions Among admitted pediatric patients, most do not have documentation of CSDs, including those with CCD and patients ?18 years of age. Improvements in both frequency and consistency of CSD documentation are needed to inform the family-centered care of patients living with CCDs.Ebola virus (EBOV) can cause severe hemorrhagic fever in humans, and no approved treatment is currently available. Although several antibodies have achieved good protection in animal models, the potential emerging isolates of ebolavirus and the unknown effects of experimental antibodies in humans underscore the need to develop additional antibodies to address the threat of Ebola. Here, we isolated a series of memory B cell-derived monoclonal antibodies from healthy Chinese adults vaccinated with Ad5-EBOV. These antibodies were encoded by diverse germline genes and had high levels of somatic hypermutation. Most antibodies were cross-reactive and could bind at least two ebolavirus glycoproteins (GPs). Seven neutralizing antibodies were identified using HIV-EBOV GP-Luc pseudovirus, and they effectively neutralized authentic EBOV. In particular, monoclonal antibody 2G1 exhibited potent cross-neutralization against HIV-EBOV/SUDV/BDBV GP-Luc bearing different ebolavirus GPs. We used truncated GPs, competition assays, and software prediction to analyze seven neutralizing antibodies, which bound four different epitopes on GP. Importantly, three of these antibodies provided complete protection in mice when administered one day post-infection. Our study expands the list of candidate antibodies and the options for successfully treating ebolavirus infection.p53 is the most frequently mutated gene in human cancers, with over half of all tumors harboring mutation at this locus. R248 and R249 (corresponding to porcine R241 and R242), are among the hotspot mutations frequently mutated in liver, lung, breast, and some other cancers. In this study, p53 gene was knocked out or point-edited (R241 and R242 were converted to 241W and 242S) in porcine fetal fibroblast (PFF) cells via CRISPR-Cas9 technique. High throughput sequencing of miRNA and mRNA uncovered a total of 225 differentially expressed miRNAs (DEMs) and 738 differentially expressed genes (DEGs) in the p53 knockout (p53-KO) cells, and a total of 211 DEMs and 722 DEGs in the point-modified (p53-241W242S) cells. Totally 28 annotated DEMs were found to overlap between p53-KO/p53-WT and p53-241W242S/p53-WT miRNAs datasets, of which miR-34&nbsp;c, miR-218, miR-205, miR-105-1, miR-105-2, miR-206, miR-224 and miR-429 play important roles in p53 regulatory network. Among the top 10 DEGs in p53-KO and p53-241W242S cells, most genes were reported to be involved in tumors, cell proliferation or cell migration. p53-KO and p53-241W242S cells showed a significantly higher (P&nbsp; less then &nbsp;0.01) proliferation rate compared with p53-WT cells. In conclusion, genetic modifications of p53 gene significantly affect the expression levels of a large number of genes and miRNAs in the PFF cells. The p53-edited PFF cells could be used as non-tumor cell models for investigating the p53 signaling network, and as donor cells for somatic nuclear transfer, with the aim to develop porcine models with the corresponding p53 mutations.Abbreviations CRISPR-Cas9 Clustered regularly interspaced short palindromic repeats-associated protein 9; PFF porcine fetal fibroblasts; SCNT somatic cell nuclear transfer; RNA sequencing small RNA sequencing and mRNA sequencing; DEGs differentially expressed mRNAs; DEMs differentially expressed miRNAs.